Table 2.
Hsp90 inhibitors
| Inhibition type | Subtype | Inhibitor and references |
|---|---|---|
| Targeting Hsp90 ATPase Activity | Ansamycins | Geldanamycin (GM)649 |
| Tanespimycin (17-AAG)650 | ||
| Alvespimycin (17-DMAG)651 | ||
| Retaspimycin hydrochloride (IPI-504)652 | ||
| Non-ansamycins | Luminespib (AUY922)653 | |
| Ganetespib (STA-9090) | ||
| BIIB021 | ||
| Onalespib (AT13387)656 | ||
| SNX-5422 (PF-04929113) | ||
| Blocking Hsp90 C-terminal ATPase activity | Novobiocin658,659 | |
| Deguelin660 | ||
| Epigallocatechin gallate (ECGC)662 | ||
| Disrupting Hsp90 and Its Co-chaperones | Targeting Hsp90-Cdc37 complex | Celastrol663–667 |
| Aferin A | ||
| Sulforaphane | ||
| Kongensin A | ||
| Platycodin D | ||
| Pep-1668 | ||
| Targeting Hsp90-Hop-Hsp70 complex | Six active compounds669 | |
| Blocking Deacetylation of Hsp90 | Vorinostat (SAHA)670 | |
| LAQ824671 | ||
| Romidepsin672 | ||
| Hsp90 cleavage | Enzymatic cleavage | Histone deacetylase inhibitors675 |
| Proteasome inhibitors676 | ||
| Non-enzymatic cleavage | Ascorbate/Menadione674 | |
| Oxidative stress (H2O2) |